Form 4: Co-Diagnostics President Reports Stock Transactions

Richard David Abbott, President of Co-Diagnostics, Inc., reported transactions involving restricted stock units and common stock, including a sale to cover tax withholding obligations.

Summary

• Richard David Abbott, President of Co-Diagnostics, Inc. (CODX), filed a Form 4 detailing stock transactions on May 23, 2026.
• The transactions include the acquisition of 1,890 shares of common stock, valued at $0.00, which were part of restricted stock units (RSUs).
• These RSUs were awarded on April 26, 2024, and August 13, 2025, under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, with vesting scheduled in installments.
• Additionally, 680 shares of common stock were disposed of at a price of $5.07 per share.
• This disposition represents shares sold to cover tax withholding obligations related to the vesting of RSUs, a mandatory 'sell to cover' transaction as per the issuer's equity incentive plans.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports standard insider transactions related to equity compensation and tax obligations, rather than strategic business developments.

Positives

• The acquisition of 1,890 shares through RSUs indicates continued equity-based compensation for the President, aligning management's interests with the company.
• The vesting schedule for RSUs suggests a long-term incentive structure designed to retain key personnel.

Negatives

• The disposal of 680 shares, even if for tax withholding, represents a reduction in the reporting person's direct holdings.

Risks

• The 'sell to cover' transaction, while standard for tax withholding, could be perceived negatively by the market if not clearly understood as non-discretionary.
• Future vesting and potential 'sell to cover' transactions could lead to further dilution or downward pressure on the stock price if not managed effectively.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Management Comments

• The sale of 680 shares 'represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSU's.'
• 'This sale is mandated by the Issuer's election, under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.'

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The 'sell to cover' mechanism for RSUs is a common practice in the biotech and diagnostics sector to manage tax liabilities without requiring the executive to use personal funds.

Stakeholder Impact

• Shareholders: The 'sell to cover' transaction may lead to a minor increase in the number of shares available in the market, though it is a pre-planned event for tax purposes.
• Employees: The continued use of RSUs reinforces the company's commitment to equity-based compensation for its executives.
• Management: The reporting person's holdings are affected by the vesting and subsequent tax settlement of RSUs.

Next Steps

• Continued vesting of restricted stock units according to the established schedule.
• Potential future 'sell to cover' transactions to satisfy tax withholding obligations upon subsequent RSU vesting.

Key Dates

Keywords

Form 4, SEC Filing, Co-Diagnostics, CODX, Richard David Abbott, Stock Transaction, Restricted Stock Units, RSU Vesting, Sell to Cover, Tax Withholding, Insider Trading